Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Commission (EC) ...

Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval ...

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Rahway, New Jersey Thursday, November 20, 2025, 14:00 Hrs [IST] ...

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...

The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...

Only one clinical-stage asset from the ProfoundBio acquisition remains in development: The antibody-drug conjugate Rina-S, in ...

Merck has agreed to acquire Cidara Therapeutics, a biotech company developing a drug designed to prevent the flu.

Merck will acquire Cidara Therapeutics for $9.2B to expand its respiratory portfolio, driven by demand for CD388 as ...